Incyte Corporation

This study tested three treatments for people with advanced head and neck cancer that had come back or spread. The goal was to see if adding epacadostat to pembrolizumab (an immunotherapy) worked better than pembrolizumab alone or standard chemotherapy. The trial included 89 adul…

This study tested a drug called pemigatinib in 47 people with a rare type of blood cancer caused by a specific gene change (FGFR1 rearrangement). The goal was to see if the drug could make the cancer disappear or shrink. The drug works by blocking the faulty protein that drives t…

This study tested a new combination of two drugs (pembrolizumab and epacadostat) against the usual treatments (sunitinib or pazopanib) for people with advanced kidney cancer that had not been treated before. The goal was to see if the new combo worked better at shrinking tumors a…

This study tested a cream called ruxolitinib on 49 people with genital vitiligo, a condition that causes white patches on the genitals. Participants applied the cream twice a day for up to 48 weeks to see if it made the patches less noticeable. The goal was to improve appearance,…

This study tested a new drug combination (itacitinib plus osimertinib) in 59 adults with advanced non-small cell lung cancer that has a specific genetic mutation (EGFR). The goal was to see if the combination is safe and helps shrink tumors. Participants received both drugs, and …

This study tested whether adding an immunotherapy drug (INCMGA00012) to standard chemotherapy (carboplatin-paclitaxel) helps people with advanced anal cancer that cannot be removed by surgery. The trial included 308 adults who had not received chemotherapy for their advanced dise…

This study looked at how safe and effective a combination of two drugs (tafasitamab and lenalidomide) is for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to previous treatment. The study focused on including patients …

This early-phase study tested a new drug called INCA32459 in 46 people with advanced cancers that had spread or couldn't be removed. The main goal was to check safety and find the best dose. Researchers also looked for signs that the drug might shrink tumors. The study is now com…

This study tested a new drug called povorcitinib in 619 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Participants received either the drug or a placebo for 12 weeks, followed by an extension period. The main goal was to see if the drug c…

This study tested whether adding the drug itacitinib to standard steroid treatment helps people with moderate to severe acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. 439 participants received either itacitinib or a placebo along wit…

This study tested a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 61 people with advanced solid tumors, including melanoma, who had run out of standard options. The goal was to find the safest dose and see if the drugs could shrink tumors…

This study tested adding the targeted drug ruxolitinib to standard chemotherapy for children and young adults with a high-risk form of acute lymphoblastic leukemia. The goal was to see if the combination could improve the chance of staying cancer-free for three years. The study i…

This study tested a new drug called povorcitinib in 608 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful boils. The goal was to see if the drug reduces flare-ups and improves symptoms compared to a placebo over 12 weeks, with …

This study tested a drug called itacitinib in 4 people with a bone marrow cancer called myelofibrosis who had already taken other treatments (ruxolitinib or fedratinib). The goal was to see if itacitinib is safe and can shrink an enlarged spleen, a common problem in this disease.…

This study tested a cream called ruxolitinib in 204 adults with prurigo nodularis, a skin condition causing intense itching. The goal was to see if the cream safely reduces itch better than a placebo cream. Participants applied the cream for 12 weeks, and researchers measured itc…

This study tested a cream called ruxolitinib on adults with moderate eczema who had not gotten better with standard treatments. The goal was to see if the cream could reduce skin redness, itching, and rash. 241 adults took part, and the study compared the cream to a placebo (a cr…

This study tested a cream called ruxolitinib in 190 adults with prurigo nodularis, a skin condition that causes intense itching and hard bumps. The goal was to see if the cream could safely reduce itch better than a cream with no active ingredient. Participants applied the cream …

This study tested a new drug called povorcitinib in 136 adults with chronic spontaneous urticaria (hives and itching) that standard treatments couldn't control. Participants took the drug or a placebo for 12 weeks to see if it reduced their hive and itch scores. The goal was to f…

This early-stage study tested a new drug called INCB160058 in 137 healthy adults aged 18 to 55. The main goal was to check the drug's safety and how the body processes it, not to treat any disease. Participants took a single dose by mouth, and researchers monitored side effects a…

This study looked at how a single dose of a drug called INCB123667 is absorbed, broken down, and removed from the body in 9 healthy men aged 18 to 55. Participants took the drug by mouth, and researchers measured radioactivity in blood, urine, and stool to track the drug's path. …

This study tested a new way to collect fluid from the skin using a tiny microneedle patch. Researchers compared samples from 20 healthy volunteers and people with eczema (atopic dermatitis) to see how much fluid could be collected and how well it was tolerated. The goal was to le…

This study looked at how a single dose of a drug called INCB099280 moves through and leaves the body. Five healthy men took one pill, and researchers measured the drug and its breakdown products in blood, urine, and stool. The goal was to understand the drug's balance and metabol…

This study looked at how three common drugs (itraconazole, rifampin, and acid reducers) change the way the body handles a new medicine called INCB161734. It involved 63 healthy adults aged 18 to 55. The goal was to measure drug levels in the blood and check for side effects, help…